{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid =
| IUPAC_name = 8-bromo-6-(2-fluorophenyl)-1-methyl-4''H''-[1,2,4]triazolo[4,3-a] [1,4]benzodiazepine
| image = Flubromazolam.svg
| width = 200

<!--Clinical data-->
| tradename = 
| legal_CA = Schedule IV
| legal_US = Unscheduled 
| legal_US_comment = (Schedule I in Virginia)
| legal_status = Illegal in Sweden and Switzerland

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 612526-40-6
| PubChem = 21930924
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 10684757
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 1BF1HN5GWD

<!--Chemical data-->
| C=17 | H=12 | Br=1 | F=1 | N=4
| molecular_weight =
| smiles = BrC1=CC3=C(C=C1)[N]2C(=NN=C2C)CN=C3C4=C(C=CC=C4)F
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H12BrFN4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VXGSZBZQCBNUIP-UHFFFAOYSA-N
}}

'''Flubromazolam'''<ref>{{cite web | url=https://www.google.com/patents/EP0072029B1 | title=Patent EP 0072029 B1 - Triazolobenzazepines, process and intermediates for their preparation and medicines containing them | date=22 October 1986 | accessdate=6 August 2015 |author1=René Borer |author2=Max Gerecke |author3=Emilio Kyburz }}</ref><ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/jm00293a015 | title=6-Phenyl-4H-s-triazolo[4,3-a] [1,4]benzodiazepines which have central nervous system depressant activity |author1=Jackson B. Hester Jr. |author2=Allan D. Rudzik |author3=Bharat V. Kamdar | journal=Journal of Medicinal Chemistry |date=November 1971  | volume=14 | issue=11 | pages=1078–1081 | doi=10.1021/jm00293a015 | pmid=5165540}}</ref> is a [[benzodiazepine]] derivative closely related to [[triazolam]] and [[flubromazepam]] that has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/16435 | title=Flubromazolam | publisher=Cayman Chemical | accessdate=20 November 2015}}</ref><ref>{{cite journal | author1=Laura M. Huppertz | url=https://link.springer.com/article/10.1007/s11419-015-0277-6 | title=Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites | date=July 2015 | author2=Philippe Bisel | author3=Folker Westphal | author4=Florian Franz | author5=Volker Auwärter | author6=Bjoern Moosmann | journal=Forensic Toxicology | volume=33 | issue=2 | pages=388–395 | doi=10.1007/s11419-015-0277-6}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S2352007816300531 | title=Exploration des métabolites de 8 benzodiazépines de synthèse | author1=M. Chaslot | author2=S. El Balkhi | author3=T. Robin | author4=J. Morichon | author5=N. Picard | author6=F. Saint-Marcoux | journal=Toxicologie Analytique et Clinique | date=June 2016 | volume=28 | issue=2 | pages=S32 | doi=10.1016/j.toxac.2016.03.053}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.2003/abstract | title=Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays |author1=Madeleine Pettersson Bergstrand |author2=Anders Helander |author3=Therese Hansson |author4=Olof Beck | journal=Drug Testing and Analysis | date=2016 | doi=10.1002/dta.2003 | pmid=27366870}}</ref><ref>{{cite journal|first1=Gudrun|last1=Høiseth|first2=Silja Skogstad|last2=Tuv|first3=Ritva|last3=Karinen|title=Blood concentrations of new designer benzodiazepines in forensic cases|url=http://www.sciencedirect.com/science/article/pii/S0379073816304121|journal=Forensic Science International|doi=10.1016/j.forsciint.2016.09.006|date=2016|volume=268|pages=35–38|pmid=27685473}}</ref> Flubromazolam is reputed to be highly potent, and concerns have been raised that [[clonazolam]] and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong [[sedation]] and [[amnesia]] at oral doses of as little as 0.5&nbsp;mg.<ref>{{cite journal | author1=Bjoern Moosmann | title=Designer benzodiazepines: A new challenge | date=June 2015 | author2=Leslie A King | author3=Volker Auwärter | journal=World Psychiatry | volume=14 | issue=2 | pages=248 | doi=10.1002/wps.20236 | pmid=26043347 | PMC=4471986}}</ref> Life-threatening adverse reactions have been observed at doses of only 3&nbsp;mg of flubromazolam.<ref>{{cite journal | author1=Magdalena Łukasik-Głębocka | url=http://www.tandfonline.com/doi/full/10.3109/15563650.2015.1112907 | title=Flubromazolam – A new life-threatening designer benzodiazepine | date=2016 | author2=Karina Sommerfeld | author3=Artur Teżyk | author4=Barbara Zielińska-Psuja | author5=Paweł Panieński | author6=Czesław Żaba | journal=Clinical Toxicology | volume=54 | issue=1 | pages=66–68 | doi=10.3109/15563650.2015.1112907 | pmid=26585557}}</ref>

==Legal status==

=== Sweden ===
Flubromazolam has been classified as an illegal substance in Sweden after seizures by customs and police, as well as indications from the [[European Monitoring Centre for Drugs and Drug Addiction|EMCDDA]] of wider use as a recreational drug.<ref>{{cite web | url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/mars/fler-amnen-foreslas-bli-klassade-som-narkotika-eller-halsofarlig-vara/ | title=Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara  | publisher=Folkhälsomyndigheten | language=Swedish}}</ref>

=== Switzerland ===
Flubromazolam is illegal in Switzerland as of December 2015.<ref>{{cite web | url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html | title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien | publisher=Der Bundesrat | language=German}}</ref>

=== United Kingdom ===
In the UK, flubromazolam has been classified as a [[Drugs controlled by the UK Misuse of Drugs Act|Class C drug]] by the May 2017 amendment to [[Misuse of Drugs Act 1971|The Misuse of Drugs Act 1971]] along with several other designer benzodiazepine drugs.<ref>{{Cite web|url=http://www.legislation.gov.uk/uksi/2017/634/contents/made|title=The Misuse of Drugs Act 1971 (Amendment) Order 2017|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

=== United States ===

Clonazolam, Flubromazepam, Flubromazolam have now all been placed into Schedule I under Virginia State Law.<ref>{{Cite web|url=http://law.lis.virginia.gov/admincode/title18/agency110/chapter20/section322/}}</ref>

==See also==
{{Colbegin}}
* [[3-Hydroxyphenazepam]]
* [[Adinazolam]]
* [[Desmethyletizolam]]
* [[Desmethylflunitrazepam]]
* [[Diclazepam]]
* [[Etizolam]]
* [[Meclonazepam]]
* [[Nifoxipam]]
* [[Phenazepam]]
* [[Pyrazolam]]
{{Colend}}

==References==
{{Reflist}}

{{Benzodiazepines}}
{{GABAAR PAMs}}

[[Category:Benzodiazepines]]
[[Category:Bromoarenes]]
[[Category:Fluoroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Triazolobenzodiazepines]]


{{sedative-stub}}